What is ESA in cancer?

What is ESA in cancer?

A substance that stimulates the bone marrow to make more red blood cells. ESAs are used to treat anemia caused by chronic kidney failure, some anticancer drugs, and certain treatments for HIV. They may also be used to lower the number of blood transfusions needed during and after certain major surgeries.

What does ESA mean in medical terms?

Erythropoietin stimulating agents (also called ESA medicines) are used to treat anemia caused by chronic kidney disease or chemotherapy for cancer treatment. They may also be used to treat anemia caused by taking medicines for human immunodeficiency virus (HIV). Or they may be given for certain types of surgeries.

What is ESA in hematology?

Sed rate, or erythrocyte sedimentation rate (ESR), is a blood test that can reveal inflammatory activity in your body. A sed rate test isn’t a stand-alone diagnostic tool, but it can help your doctor diagnose or monitor the progress of an inflammatory disease.

What are the ESA products?

The following types of ESAs are available:

  • Erythropoietin (Epo)
  • Epoetin alfa (Procrit, Epogen)
  • Epoetin beta (NeoRecormon)
  • Epoetin zeta (Silapo, Retacrit)
  • Darbepoetin alfa (Aranesp)
  • Methoxy polyethylene glycol-epoetin beta (Mircera)

What is ESA injection?

Recombinant erythropoietin drugs are known as erythropoietin-stimulating agents (ESAs). These drugs are given by injection (shot) and work by stimulating the production of more red blood cells. These cells are then released from the bone marrow into the bloodstream.

How are ESA administered?

ESA can be given intravenously or subcutaneously. The route of administration of ESA will be determined by patient-oriented issues, treatment setting, efficacy considerations and the class of ESA being prescribed. For patients undergoing peritoneal dialysis, subcutaneous administration is the only route feasible.

What is ESA in dialysis?

Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia associated with chronic kidney disease (CKD).

When do you initiate ESA?

o Initiate ESA treatment when the hemoglobin level is less than 10 g/dL. o If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of ESA. When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly.